China
Africa
Explore chapters and articles related to this topic
Lockdown as a Strategy to Control COVID-19
Published in Hanadi Talal Ahmedah, Muhammad Riaz, Sagheer Ahmed, Marius Alexandru Moga, The Covid-19 Pandemic, 2023
Naheed Bano, Rizwan Ahmad, Zahid Khan, Majid Khan
Interventions like self-quarantine, vacations, and isolation of high-risk population helped in controlling the corona [35]. The primary response from many countries was the first-level response, and mainly people not responded. And in the start, people not responded positively and not isolated themselves. Still, after some time, they responded, and the number of self-quarantine adoption increased, which helped control the pandemic [36, 37]. Some other problems were a shortage of hospital beds and medicine [38, 39].
The Large Bowel and the Anal Canal
Published in E. George Elias, CRC Handbook of Surgical Oncology, 2020
A second high risk population besides aging would be those who have had polyps or cancer of the bowel before and their first degree relatives. The lifetime risk from large bowel cancer in the first degree relative is 10 to 15%.23
Management of the older patient after myocardial infarction
Published in Wilbert S. Aronow, Jerome L. Fleg, Michael W. Rich, Tresch and Aronow’s Cardiovascular Disease in the Elderly, 2019
Howard A. Cooper, Julio A. Panza, Wilbert S. Aronow
The incidence and prevalence of diabetes increase with age, due to both increased insulin resistance (from adiposity and sarcopenia) and impaired insulin secretion (due to pancreatic islet cell dysfunction) (60). The prevalence of diabetes is expected to double by 2050, with the largest increase expected in those ≥75 years of age (61). In addition, older persons with both diabetes and CHD are an especially high-risk population. For example, among over 2000 elderly patients (mean age 80 ± 8 years), diabetes was associated with an increase in the relative risk of new coronary events 1.9 times in men and 1.8 times in women (10). Despite this, many elderly patients with diabetes go undiagnosed (62). Therefore, all older post-MI patients should be screened for the presence of diabetes.
Changes in physical activity and sedentary time among children with asthma during the COVID-19 pandemic and influencing factors
Published in Journal of Asthma, 2023
Sandra Lee, Ai Zhang, Lei Liu, Deborah Salvo, Leyao Wang
Children with asthma may have faced multiple challenges during the COVID-19 pandemic that were neglected, such as changes in physical activity and sedentary time, which may have long-term impacts on clinical manifestations. It has been reported that adults with asthma had a significantly greater decline in physical activity and were found to be spending more time sitting during the pandemic compared to their healthy counterparts (12). However, the changes in physical activity among children with asthma have not been evaluated. Therefore, it is essential to measure the impact on this high-risk population. The aim of this study was to document levels of physical activity and sedentary time before and during the COVID-19 pandemic among children with asthma, and to explore differences by individual, parental, and organizational characteristics.
The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma
Published in Expert Opinion on Pharmacotherapy, 2022
Janelle Schweitzer, Meghan Hoffman, Solomon A. Graf
The aforementioned studies have established the current role of umbralisib for treating relapsed and refractory FL and MZL. Results from several ongoing and potential future studies are needed to confirm these data and, potentially, determine any broader applications for umbralisib. The National Clinical Trials Network is running a 3-arm randomized phase II study for early-relapsed FL (target recruitment 150 patients, NCT03269669), noted previously as an area of unmet need [8,32,33]. Patients with FL relapsed within 24 months of initial chemoimmunotherapy are treated with the anti-CD20 antibody obinutuzumab plus umbralisib for up to 1 year (arm 1) versus obinutuzumab plus lenalidomide for up to 1 year (arm 2) versus obinutizumab plus cytotoxic chemotherapy (regimen determined according to prior treatments, arm 3). Results of this study will be important for addressing this high-risk population currently lacking a defined optimal treatment[34]. The large, randomized phase IIb UNITY NHL trial is accruing up to 900 patients with previously treated B-NHL of various histologies including FL and MZL. Subjects are treated on one of several arms including umbralisib alone, combined with the novel, glycoengineered anti-CD20 antibody ublituximab, or with ublituximab plus bendamustine (NCT02793583). Data will hopefully define the tolerability and efficacy of umbralisib alongside other B-NHL therapeutics in the R/R space.
The Marcus Institute for Brain Health: an integrated practice unit for the care of traumatic brain injury in military veterans
Published in Brain Injury, 2021
Catharine H. Johnston-Brooks, Riley P. Grassmeyer, Christopher M. Filley, James P. Kelly
The MIBH was inaugurated in 2017 as an interdisciplinary evaluation and treatment program for Veterans and other adults who experience PPCS and related behavioral health problems. At the heart of this program are many clinical modalities, each uniquely contributing to the diagnostic evaluation, clinical understanding, and subsequent treatment of patients who present with a wide array of symptoms requiring a comprehensive approach. Patients who seek out the MIBH often express frustrations with the traditional medical model of individual outpatient clinic visits without a coordinated plan of care. Such a model is fraught with logistical, communication, and emotional challenges when there are many interwoven comorbidities in a high-risk population. The MIBH seeks to avert these frustrations by offering integrated treatment from multiple disciplines co-located in a comprehensive program.